STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

A personalized mRNA cancer vaccine, added to an existing treatment, slowed the return of melanoma and its spread to other parts of the body in a late-stage clinical trial, the drugmakers Merck and Moderna announced Wednesday, results that could herald a new, powerful approach in oncology. So-called “neoantigen” vaccines have long been seen as having potential as cancer treatments, but this is the first randomized Phase 3 clinical trial aimed at definitively proving their benefit. In this case th...